Abstract
Although none of the known tumor markers, including the relatively new ones characterized by monoclonal antibodies, are sufficiently sensitive or specific as to be useful in the primary diagnosis of incipient malignancies, many of them turned out, nevertheless, to be of great clinical importance: their main field of interest lies in the surveillance of the already diagnosed patient in the post-operative phase. More recently some of them, e.g. tumor proteins like CEA and AFP, hormones (HCG), some enzymes, and monoclonal antibody-characterized membrane components, are used also as target antigens for the radioimmuno-detection (RAID) of carcinomas and their metastases. Most of the tumor marker antigens were already successfully used as targets for tumor imaging with radiolabelled antibodies; however, many immunological and technical problems still remain to be resolved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
